Therapeutic Targeting of RAS Mutant Cancers
Published on 14. September 2022
978-1-009-07525-1 (ISBN)
Description
The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting features unique to specific oncogenic mutations. This has led to the first FDA approval for a RAS targeted therapy. This new agent is a covalent inhibitor that reacts with the cysteine residue created by a codon 12 glycine to cysteine (G12C) mutation within KRAS. Mutant-specific strategies may also exist for other KRAS single nucleotide variants, and recent studies provide examples and mechanisms.
More details
Series
Language
English
Place of publication
Cambridge
United Kingdom
Target group
Professional and scholarly
Illustrations
Worked examples or Exercises
File size
1,87 MB
ISBN-13
978-1-009-07525-1 (9781009075251)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions
Edward C. Stites | Kendra Paskvan | Shumei Kato
Therapeutic Targeting of RAS Mutant Cancers
Book
09/2022
Cambridge University Press
€24.00
Shipment within 15-20 days
Persons
Content
Introduction; RAS Biology; Oncogenic RAS; RAS Targeting; Downstream Targeting; Upstream Targeting; Targeting Specific RAS Mutants; KRAS G12C Targeting; Direct Targeting of Other RAS Proteins; KRAS G12R Pancreatic Cancer; KRAS G13D Colorectal Cancer; Summary; References.
